NCT07817784Not yet recruiting
Indonesian Version of Oxford Cognitive Screen-Plus Test in Stroke Patient
Validity and Reliability Test of the Indonesian Version of Oxford Cognitive Screen-Plus in Stroke Patient
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The incidence of stroke increases every year throughout the world. Neuropsychological assessment is the best way to identify post-stroke cognitive dysfunction. The importance of cognitive function in the post stroke rehabilitation program process requires a tool that can detect cognitive disorders more specifically and more sensitively. The investigator aim in this study was to develop Indonesian version of the OCS - Plus among stroke patient in Indonesia.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 20 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Oct 2026
- Lead sponsor
- Universitas Padjadjaran
- Diseases
- Stroke
- NCT number
- NCT07817784
What you commit to
- Study type: Observational
- Planned participants: 75
- From Sept 2026 to the primary completion date, Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Have uncorrected severe visual and hearing impairments
- Have cognitive rehabilitation before research
- Inability to maintain concentration for approximately 30 minutes
Who the study is looking for
- Male or female18 years of age or older
- Subacute and chronic stroke patients
- Able to understand instructions
- Able to read
- Can speak Indonesian well
- Willing to take part in research
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.